Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION

17 FEB 2022

FDA ADVISORY
No. 2022-0277

TO : **ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC**

SUBJECT : **Public Health Warning Against the Purchase and Use of the following Verified Counterfeit Drug Products:**

1. **Paracetamol (Biogesic®) 500 mg tablet**
2. **Phenylephrine HCl / Chlorphenamine Maleate / Paracetamol (Bioflu®) 10 mg / 2 mg / 500 mg Film Coated Tablet**
3. **Ibuprofen / Paracetamol (Alaxan®FR) 200 mg / 325 mg capsule**
4. **Ibuprofen (Medicol®Advance) 200 mg Softgel Capsule**
5. **Phenylpropanolamine HCl / Chlorphenamine Maleate / Paracetamol (Decolgen Forte®) 25 mg / 2 mg / 500 mg Tablet**
6. **Phenylephrine HCl / Chlorphenamine Maleate / Paracetamol (Neozep® Forte) 10 mg / 2 mg / 500 mg Tablet**
7. **Mefenamic Acid (Dolfenal®) 500 mg Film-coated Tablet**

The Food and Drug Administration (FDA) advises the public against the purchase and use of the following verified counterfeit drug products:

AUTHENTIC



COUNTERFEIT



Counterfeit – The tablet, knurling, security mark, and print appearance are not comparable with the standard features of the registered product.

Figure 1. Comparison between the primary packaging (blister pack) of the Authentic and Verified Counterfeit Paracetamol (Biogesic®) 500 mg Tablet (Lot No. 20063278 Expiry date NOV 2024)

AUTHENTIC



COUNTERFEIT



Counterfeit – The tablet, knurling, security mark, and print appearance are not comparable with the standard features of the registered product.

Figure 2. Comparison between the primary packaging (blister pack) of the Authentic and Verified Counterfeit Phenylephrine HCl/ Chlorphenamine Maleate/ Paracetamol (Bioflu®) 10 mg/ 2 mg/ 500 mg Film-Coated Tablet (Lot No. U2350770 Expiry date 07/2024)

AUTHENTIC





COUNTERFEIT





Counterfeit – Knurling, security mark, and print appearance are not comparable with the standard features of the registered product.

Figure 3. Comparison between the primary packaging (blister pack) of the Authentic and Verified Counterfeit Ibuprofen/ Paracetamol (Alaxan® FR) 200 mg/ 325 mg Capsule (Lot No. 24526670 Expiry date APR 2024)

AUTHENTIC



COUNTERFEIT



Counterfeit – The capsule, knurling, security mark, and print appearance are not comparable with the standard features of the registered product.

Figure 4. Comparison between the primary packaging (blister pack) of the Authentic and Verified Counterfeit Ibuprofen (Medicol® Advance) 200 mg Capsule (Lot No. E050800 Expiry date 08/2023)

AUTHENTIC



COUNTERFEIT



Counterfeit – The tablet, knurling, and print appearance are not comparable with the standard features of the registered product.

Figure 5. Comparison between the primary packaging (blister pack) of the Authentic and Verified Counterfeit Phenylpropanolamine HCl/ Chlorphenamine Maleate/ Paracetamol (Decolgen® Forte) 25 mg/ 2 mg/ 500 mg Tablet (Lot No. 20218006 Expiry date AUG 2024)

AUTHENTIC



COUNTERFEIT



Counterfeit – The tablet, knurling, security mark, and print appearance are not comparable with the standard features of the registered product.

Figure 6. Comparison between the primary packaging (blister pack) of the Authentic and Verified Counterfeit Phenylephrine HCl/ Chlorphenamine Maleate/ Paracetamol (Neozep® Forte) 10 mg/ 2 mg/ 500 mg Tablet (Lot No. 20810322 Expiry date AUG 2024)

AUTHENTIC



COUNTERFEIT



Counterfeit – Knurling and print appearance are not comparable with the standard features of the registered product.

Figure 7. Comparison between the primary packaging (aluminum foil strip) of the Authentic and Verified Counterfeit Mefenamic Acid (Dolfenal®) 500 mg Film-Coated Tablet (Lot No. M135860 Expiry date 09/2026)

All healthcare professionals and the general public are hereby warned as to the availability of these counterfeit drug products in the market which pose potential danger or injury to consumers. Consumers are also reminded to purchase drug product only from FDA-licensed establishments.

Likewise, all establishments and outlets are hereby warned against selling and/or dispensing of the said counterfeit product with the abovementioned features. The manufacture, selling or offering for sale of such is in direct violation of Republic Act No. 9711 or the Food and Drug Administration Act of 2009, and Republic Act No. 8203 or the Special Law on Counterfeit Drugs. Anyone found selling the said counterfeit drug product will be penalized.

All concerned establishments and/or entities are warned not to distribute the above-identified violative drug product until it has been covered by the appropriate authorization, otherwise, regulatory actions and sanctions shall be strictly pursued. Always check if a product is registered with the FDA by using the **FDA Verification Portal feature** accessible at **http://verification.fda.gov.ph.**

All Local Government Units (LGUs) and Law Enforcement Agencies (LEAs) are requested to ensure that these products are not sold or made available in their localities or areas of jurisdiction.

For more information and inquiries, please e-mail us at **info@fda.gov.ph**. To report continuous sale or distribution of unregistered health products, kindly e-mail us via **ereport@fda.gov.ph**, or through the online reporting facility, **eReport**, at **www.fda.gov.ph/ereport**. You may also call the Center for Drug Regulation and Research at telephone number **(02) 8809-5596**. For any suspected adverse drug reaction (ADR), report immediately to FDA through this link: **https://primaryreporting.who-umc.org/Reporting/Reporter?OrganizationID=PH** and fill out all the required fields.

Dissemination of the information to all concerned is requested.

DR. OSCAR G. GUTIERREZ, JR.
Officer-in-Charge, Director General

DTN: 20220207123207